# Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

Study · id `cardio:ct-nct07776054` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07776054](<https://clinicaltrials.gov/study/NCT07776054>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07776054

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07776054. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07776054, source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT07776054, source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)
- Primary completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT07776054, source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)
- Completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT07776054, source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07776054, source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07776054-2026-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
- Condition: Atrial Fibrillation
- Condition: SGLT2 Inhibitor
- Condition: DC Cardioversion
- Intervention (Drug): SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: f0951d568e8843cb077c28473e8313c3ba8cb8c417b2f6d14d97a8167a595c4b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
